Does Rallies show 13F holders for TRDA?

Yes. Rallies tracks hedge fund and 13F ownership data for TRDA, including fund names, share counts, latest tracked quarter, and position changes when available.

Is TRDA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for TRDA. It does not provide personalized investment advice.

TRDA (Entrada Therapeutics, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Entrada Therapeutics, Inc. Common Stock (TRDA) is a publicly traded Healthcare sector company. As of May 21, 2026, TRDA trades at $6.18 with a market cap of $228.65M and a P/E ratio of -1.49. TRDA moved +6.73% today. Year to date, TRDA is -42.48%; over the trailing twelve months it is -26.70%. Its 52-week range spans $4.93 to $21.79. Analyst consensus is strong buy with an average price target of $19.50. Rallies surfaces TRDA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns TRDA stock?

Hedge funds tracked by Rallies that own TRDA include Redmile Group. The latest tracked quarter is Jun 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Entrada Therapeutics, Inc. Common Stock.

TRDA Key Metrics

Key financial metrics for TRDA
Metric	Value
Price	$6.18
Market Cap	$228.65M
P/E Ratio	-1.49
EPS	$-3.99
Dividend Yield	0.00%
52-Week High	$21.79
52-Week Low	$4.93
Volume	1
Avg Volume	0
Revenue (TTM)	$5.74M
Net Income	$-166.12M
Gross Margin	0.00%

Top Hedge Funds Holding TRDA

Redmile Group holds 560.97K shares of TRDA, changed -56.30% as of Jun 30, 2024.

Latest TRDA News

Entradas shares plunge after DMD therapy misses primary efficacy endpoints — May 8, 2026
Entrada Therapeutics Secures $255M Runway to Q3 2027 After ELEVATE-44 Cohort 1 Success — May 7, 2026
Entrada Therapeutics to Release Multiple Ascending Dose Phase 1/2 Cohort 1 Duchenne Study Results May 7 — May 6, 2026
Entrada Advances ELEVATE-44-201 with 12 mg/kg Dose Recommendation, $296M Cash Runway — Feb 26, 2026
Entrada Therapeutics Projects Q4 EPS Loss $1.32, Revenues Plunge 96.6% — Feb 26, 2026

Recent TRDA Insider Trades

Sethuraman Natarajan sold 25.91K (~$398.81K) on May 4, 2026.
Dowden Nathan J sold 15.00K (~$229.95K) on May 4, 2026.
WENTWORTH KORY JAMES sold 2.50K (~$32.38K) on Apr 1, 2026.

TRDA Analyst Consensus

8 analysts cover TRDA: 0 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $19.50.

Common questions about TRDA

Who owns TRDA stock?: Hedge funds tracked by Rallies that own TRDA include Redmile Group. The latest tracked quarter is Jun 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Entrada Therapeutics, Inc. Common Stock.
Does Rallies show 13F holders for TRDA?: Yes. Rallies tracks hedge fund and 13F ownership data for TRDA, including fund names, share counts, latest tracked quarter, and position changes when available.
Is TRDA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for TRDA. It does not provide personalized investment advice.